Insight Molecular Diagnostics and Upcoming Conferences
Insight Molecular Diagnostics Inc. (IMDX) is set to play a significant role in advancing kidney transplant management through its participation in two major conferences this fall. These upcoming events will take place in Singapore and Orlando, showcasing the company's innovative GraftAssure™ technology, which aims to improve patient outcomes through enhanced transplant rejection testing.
Symposium at IATDMCT Annual Meeting
On September 24, iMDx will host a symposium at the International Association of Therapeutic Drug Monitoring and Clinical Toxicology (IATDMCT) annual meeting in Singapore. This forum will focus on the growing clinical applications of the GraftAssure technology, particularly in the context of transplant rejection testing for kidney recipients. The event will emphasize the advantages of in-house testing for real-time monitoring of transplant patients.
GraftAssure Technology Demonstration
The presentation will delve into how GraftAssure can not only identify transplant rejection but also assess how well the treatment is working for patients. Previous studies have shown that iMDx's technology significantly shortens the time required to diagnose rejection, especially in patients deemed high-risk during the transplant process.
Presentation at ASHI Annual Meeting
Following the IATDMCT event, iMDx will also present at the American Society of Histocompatibility and Immunogenetics (ASHI) annual meeting in Orlando from October 6 to 10. Here, the focus will be on GraftAssureIQ, a research-use test kit developed by iMDx, which is designed for scientific study in the field of transplant immunology.
Collaboration with Bio-Rad Laboratories
At both meetings, insights will be shared not only from iMDx’s team but also from strategic partner Bio-Rad Laboratories. iMDx Chief Science Officer Dr. Ekke Schuetz will highlight the clinical research advancements and the effectiveness of in-house dd-cfDNA testing, which could greatly enhance the workflow for medical staff and care for patients.
Strategic Goals and Future Directions
Through these presentations, iMDx aims to convey the potential of its proprietary tests for kidney transplant patients. The company is approaching an important milestone with its plans to submit GraftAssureDx for FDA review by the end of the year. The expected clinical kitted version is anticipated to capture a substantial share of the $1 billion market associated with transplant rejection testing.
Scientific Background of GraftAssure
The key to GraftAssure's functionality lies in quantifying donor-derived cell-free DNA (dd-cfDNA), a biomarker that has been validated as an effective indicator of transplant rejection. This advancement places iMDx at the forefront of precision diagnostics, focusing on democratizing access to essential testing for patients.
About Insight Molecular Diagnostics Inc.
Formerly known as Oncocyte Corp. (OCX), Insight Molecular Diagnostics is dedicated to leveraging novel molecular diagnostic approaches to enhance patient care. Now headquartered in Nashville, Tennessee, iMDx is committed to innovating the landscape of transplant management with products like GraftAssureCore, GraftAssureIQ, and the upcoming GraftAssureDx.
Frequently Asked Questions
What are the upcoming conferences for iMDx?
iMDx will participate in the IATDMCT annual meeting in Singapore and the ASHI annual meeting in Orlando, focusing on kidney transplant management.
What is the GraftAssure technology?
GraftAssure is a transplant rejection testing technology that identifies transplant rejection and monitors treatment efficacy using donor-derived cell-free DNA.
Who are the key speakers for the iMDx presentations?
Key speakers include Dr. Ekke Schuetz from iMDx and representatives from Bio-Rad Laboratories, who will present collaborative research findings.
What is the significance of dd-cfDNA in transplantation?
Donor-derived cell-free DNA is an established biomarker that helps detect transplant rejection early, improving patient outcomes and management.
When is the expected FDA review for GraftAssureDx?
iMDx plans to submit GraftAssureDx for FDA review by the end of this year, representing a significant step forward in clinical testing capabilities.
